Menu Search
Equities

Vericel Corp

VCEL:NMQ

Vericel Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)59.57
  • Today's Change2.86 / 5.04%
  • Shares traded198.71k
  • 1 Year change+67.85%
  • Beta1.6854
Data delayed at least 15 minutes, as of Nov 22 2024 18:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Vericel Corp grew revenues 20.17% from 164.37m to 197.52m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -16.71m to -3.18m.
Gross margin71.47%
Net profit margin1.56%
Operating margin-0.54%
Return on assets1.00%
Return on equity1.54%
Return on investment1.12%
More ▼

Cash flow in USDView more

In 2023, Vericel Corp increased its cash reserves by 70.10%, or 35.80m. The company earned 35.31m from its operations for a Cash Flow Margin of 17.88%. In addition the company generated 3.62m cash from financing while 3.13m was spent on investing.
Cash flow per share0.1838
Price/Cash flow per share314.61
Book value per share5.23
Tangible book value per share5.10
More ▼

Balance sheet in USDView more

Vericel Corp uses little debt in its capital structure as supported by a debt to capital ratio of 0.09%.
Current ratio4.61
Quick ratio4.23
Total debt/total equity0.0009
Total debt/total capital0.0009
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.